Oncology Venture - Merger with Medical Prognosis Institute finalised
In early September, Oncology Venture AB and Medical Prognosis Institute (MPI) completed their strategic merger and the new entity, Oncology Venture A/S (OV), now trades on the NASDAQ First North Stockholm. Recently, OV’s three highest priority programmes all demonstrated progress. OV reported interim data from the LiPlaCis trial and is increasing enrolment, whereas 2X-121 received an IND from the US FDA in ovarian cancer. Furthermore, OV has a 55% stake in dovitinib, a tyrosine kinase inhibitor that was in-licensed from Novartis.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.